Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company that develops therapies for neurological disorders characterized by neuronal excitation-inhibition imbalance. The company utilizes two proprietary platforms: Cerebrum, a small molecule platform for orally available precision therapies, and Solidus, an antisense oligonucleotide platform for targeted gene modulation. Its clinical-stage portfolio includes ulixacaltamide for essential tremor, vormatrigine, relutrigine for developmental and epileptic encephalopathies, and elsunersen for early-onset SCN2A developmental and epileptic encephalopathy. The company targets patients with movement disorders and epilepsy, leveraging genetic insights to identify therapeutic targets. Praxis has an exclusive collaboration with Tenacia Biotechnology to develop and commercialize ulixacaltamide in China, Hong Kong, Macau, and Taiwan. It also maintains a partnership with UCB Biopharma, which in-licensed PRAX-020. The company employs translational tools such as quantitative electroencephalography and transgenic animal models to guide drug development and clinical trial design.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage praxismedicines.com
Sector Healthcare IR page investors.praxismedicines.com
Tags
neuroscience, epilepsy, movement disorders, small molecules, antisense oligonucleotides, precision medicine, ion channels, genetic disorders, central nervous system, Cerebrum, Solidus, ulixacaltamide, vormatrigine, relutrigine, elsunersen, PRAX-020, PRAX-080, PRAX-090, PRAX-100, Tenacia Biotechnology, UCB Biopharma
Press page —

Metrics

Valuation  
Market cap $ 8.139B
Market cap (USD) $ 8.139B
P/E -22.72
PEG —
P/BV 6.46
P/S 951.64
P/OCF -25.30
P/FCF -32.67
Dividend yield —
Turnover / mcap —
Returns  
ROE -45.8%
ROI -58.2%
ROIC -47.0%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 42
Quality score -46.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 0 8.553M 2.447M — — — —
Net profit -303.268M -182.819M -123.277M -214.029M -167.061M -61.82M -35.512M
Free cash flow -249.124M -131.757M -111.186M -185.487M -125.604M -52.623M -33.523M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 294.74 76.96 22.28 2.38 19.7 55.02 —
Price performance 12m 2.83 2.45 8.36 -0.88 -0.64 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 1.46M 763,000 4.31M 3.5M 2.5M 1.37M 110,000
Cash and deposits (USD) 18.6M 44.8M 297M 139M 61.6M 81.3M 215M 357M
Intangible assets (USD) — — — — — — — 0.00
Right-of-use assets (USD) — 1.45M 754,000 3.65M 2.9M 2.06M 1.13M 92,000
Cash flow detail
Operating cash flow (USD) — -33.4M -52.6M -125M -185M -111M -132M -249M
Purchases of property, plant and equipment (USD) — -103,000 0.00 -1.05M -444,000 -50,000 0.00 -56,000
Change in payables (cash effect) (USD) — -837,000 960,000 7.27M 3.89M -8.86M 6.71M 12.1M
Income taxes paid (cash effect) (USD) — — — — — — — -224,000
Share-based compensation (USD) — 668,000 5.21M 22.7M 28.6M 24.9M 41.4M 33.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -33.5M -52.6M -126M -185M -111M -132M -249M
Income detail
Research and development expense (USD) — 29.6M 45M 120M 155M 86.8M 152M 267M
↳ 5y CAGR +38.8% +42.8%
Total comprehensive income (USD) — — -61.8M -167M -214M -123M -182M -303M
Comprehensive income to owners (USD) — — -61.8M -167M -214M -123M -182M -303M
Reported Nov 23, 2020 Mar 17, 2021 Feb 28, 2022 Feb 28, 2022 Feb 7, 2023 Mar 5, 2024 Feb 28, 2025 Aug 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 12, 2026, Praxis Precision Medicines, Inc. (the “Company”) hosted an Investor Day event (“Investor Day”). The presentation used at Investor Day is available in the “Investors + Media” portion of the Company’s website at investors.praxismedicines.com and a copy is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Other Events

On November 12, 2026, at Investor Day, Company management presented on the Company’s commercial strategy and launch plans for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (“DEEs”) and ulixacaltamide in essential tremor (“ET”) and provided an update on its expanded development pipeline. The Company shared the following updates: Ulixacaltamide
•The Company provided an updated population-based prevalence estimate for ET of about 9 million people in the U.S., including about 2 million who are seeking treatment today and who represent the Company’s initial commercial focus. •The Company provided sensitivity analyses of the Essential3 primary endpoint, including key sensitivity analyses requested by the U.S.

FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing

Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies (DEEs) expected in the fourth quarter of 2026

Cash and investments of approximately $1.3 billion as of September 30, 2026 maintain runway into 2028

Praxis to host an in-person and virtual Investor Day on November 12, 2026 and will participate in a fireside chat at the Guggenheim Biotech Summit today, November 9 at 9:30am (register here)

BOSTON, November 9, 2026 — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter of 2026.

“We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company. Our teams are working to bring relutrigine and ulixacaltamide to patients who need new options.

November 4, 2026

PDF Version

BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on November 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 23,219 shares of its common stock to fifty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts: Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors [email protected] 617-430-7576

Primary Logo

Prompts

Praxis Precision Medicines, Inc. (ticker PRAX), listed in United States.

ETFs Holding Praxis Precision Medicines, Inc.

ETF Weight in ETF Shares Market value As of
PINK 1.00% 10,943 $ 3.338M Nov 17, 2026
LFSC 0.98% 3,548 $ 1.243M Aug 31, 2026
MMSC 0.96% 1,549 $ 480.608K Nov 16, 2026
MEDI 0.90% 1,173 $ 380.943K Nov 12, 2026
GSC 0.90% 7,150 $ 2.505M Aug 31, 2026
HELX 0.86% 718 $ 240.379K Jun 30, 2026
GDOC 0.73% 406 $ 142.222K Aug 31, 2026
FMED 0.68% 1,000 $ 350.3K Aug 31, 2026
JSML 0.63% 7,368 $ 2.268M Jul 31, 2026
FSEG 0.55% 94 $ 31.47K Jun 30, 2026
ESSC 0.40% 473 $ 145.604K Jul 31, 2026
MSSM 0.31% 6,296 $ 2.205M Aug 31, 2026
FESM 0.28% 48,800 $ 16.338M Jun 30, 2026
RESM 0.27% 30 $ 10.044K Jun 30, 2026
FTKI 0.27% 219 $ 67.949K Nov 16, 2026
TMSL 0.26% 20,824 $ 6.972M Jun 30, 2026
RUSC 0.25% 601 $ 201.209K Jun 30, 2026
FFSM 0.21% 10,155 $ 3.126M Jul 31, 2026
VFMO 0.20% 11,024 $ 3.862M Aug 31, 2026
CLSE short -0.20% -5,034 $ -1.763M Aug 31, 2026
SEIS 0.14% 2,475 $ 828.605K Jun 30, 2026
FFF 0.14% 31 $ 9,028.13 Sep 30, 2026
FSEV 0.10% 20 $ 6,695.80 Jun 30, 2026
FBCG 0.07% 14,899 $ 4.586M Jul 31, 2026
IALT short -0.06% -16,572 $ -5.142M Nov 16, 2026
AVIE 0.04% 22 $ 6,825.94 Nov 16, 2026
DFAS 0.01% 12,553 $ 4.077M Nov 12, 2026
AVLC 0.01% 732 $ 227.118K Nov 16, 2026
DFUS 0.01% 5,630 $ 1.828M Nov 12, 2026
AVUS 0.00% 1,818 $ 564.071K Nov 16, 2026
AVSU 0.00% 7 $ 2,171.89 Nov 16, 2026
NTRL short 0.00% -438 $ 0.00 Nov 16, 2026